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INTRODUCTION:  Around  400,000  silicone  gel  breast  implants  produced  by  the  French  company  poly
implant  prothese  (PIP)  were  used  worldwide.  Following  revelations  that  the  company  were  using non-
medical  grade  silicone  for the  production  of  their  implants  there  has  been  growing  concern  over  the
increased  rupture  rate  of  these  implants  and  the  implications  this  may  have  on  patients.
PRESENTATION  OF  CASE:  We  report  the  case  of a 57-year  old lady  with  ruptured  bilateral  cosmetic  PIP
breast  implants  in whom  a right  breast  lesion  was  detected  on screening  mammograms.  Biopsies  demon-
strated  a grade  1 tubular  carcinoma.  Histology  from  the  sentinel  lymph  node  biopsy  showed  axillarymplant rupture
entinel lymph node biopsy
reast cancer
silicone  granulomas  but  no evidence  of  metastatic  disease.
DISCUSSION:  To our knowledge,  this  is the ﬁrst reported  case  to  describe  SLNB  in  the  presence  of ruptured
PIP  implants,  although  SLNB  in  ruptured  non-PIP  implants  has been  previously  described.
CONCLUSION:  We  conclude  that  SLNB  can  be  utilised  even  in  the  context  of  concurrent  PIP  implant  rupture
and  the  presence  of silicone  granulomas  in the  axillary  lymph  nodes.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Around 400,000 silicone gel breast implants produced by the
rench company poly implant prothese (PIP) were used world-
ide. Initially, the gel used was the standard medical grade Nusil
ed3-6300 (Nusil Technology LLC, Carpinteria, CA).1 The com-
any however gained notoriety in 2011 when it was revealed
hat they were manufacturing implants with unapproved, in-
ouse manufactured industrial-grade gel (PIP1 and PIP2) instead
f medical-grade silicone. The PIP gels contained lower molecu-
ar weight silicone which had an increased propensity to diffuse
hrough the implant shell and also had an irritant potential, causing
ocal inﬂammatory reactions1 Figs. 1–3
Since this has come to light there has been growing concern
ver the increased rupture rate of these implants and the implica-
ions this may  have on patients. However, the UK government has
eported that there is no evidence that the implants pose any harm
o human health.2
In France, breast cancer has been found in 64 women  with PIP
reast implants but French health authorities insist there is still no
roven link with the disease.3 Despite reports of breast cancer in
atients with PIP implants there are no reported cases in the liter-
ture to evaluate the role of sentinel lymph node biopsy (SLNB) in
he presence of a ruptured PIP implant. Given that 1 in 8 women
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will develop breast cancer throughout their lives4 it is likely that
the assessment of sentinel lymph nodes in the presence of a rup-
tured PIP implant will become a signiﬁcant problem in the future.
In the presence of ordinary silicone implants there is a theoretical
risk that SLNB may  be unsuccessful leading to a falsely negative
result.5 The possibility of disrupted lymphatic channels from pre-
vious breast augmentation has been examined previously6 with a
100% success rate in localising the sentinel lymph node. The impact
of the use of non-medical grade silicone in PIP implants and its
effect on lymphatic mapping in SLNB is unknown.
Warbick-Smith et al. (2012)7 recently reported a case-report
of SLNB performed in the context of ipsilateral non-PIP implant
rupture. Our case report is the ﬁrst to our knowledge of a lady with
ruptured PIP implants who underwent surgery for breast cancer
and had a SLNB.
2. Case report
Patient X, aged 57 years, underwent bilateral cosmetic augmen-
tation mammoplasty with PIP implants at another institution 7
years ago. The implants used were 330 mls  each and were placed
via infra-mammary incisions in the subglandular position. At her
third round of screening on the NHS Breast Screening Programme
(NHSBSP), she was recalled after a suspicious opacity was identiﬁed
on her right mammogram.
Clinical examination conﬁrmed bilateral grade 3 capsular con-
tractures with no palpable breast lumps. Mammography showed
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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suggested that SLNB was  viable even in breasts exposed to leak-Fig. 1. Right mammogram CC and MLO  views (left to right).
 small density adjacent to the right implant in the lower half of
he breast which was best seen on the oblique view. An ultrasound
can failed to identify any abnormality and an MRI  was performed
or further assessment.
This showed that both implants had ruptured and demonstrated
he presence of silicone in the right axillary and left retropectoral
odes. The gadolinium enhanced images revealed a lesion in the
ight breast measuring 9 mm in diameter. A repeat ultrasound scan
howed a small echo-poor mass in the right breast at the site of
he MRI  abnormality and silicone ﬁlled nodes in the right axilla.
s these nodes did not appear suspicious a biopsy or FNA was  not
erformed preoperatively.
Histology of a core biopsy specimen revealed a grade1 ER posi-
ive Her2 negative tubular carcinoma in the right breast and the
atient was counselled for ultrasound skin-marked breast con-
ervation surgery and sentinel lymph node biopsy using the dual
echnique for localisation.
One day prior to surgery, the patient had injection of the radio-
sotope Tc99 into the right breast and ultrasound guided skin
arking of the breast lesion itself. Sentinel lymph node biopsy was
erformed by subareolar injection of 2 ml  of Patent Blue dye and
entinel nodes were identiﬁed using the dual technique. Lymph
odes which were both blue and had high signals were excised
ith the largest measuring 15 mm.  Intra-operative assessment ofhe axilla revealed no palpable residual lymphadenopathy. Speci-
en X-ray revealed adequate circumferential margins but spicules
owards the deep margin, closest to the implant surface.
Fig. 3. Histology of SLN showing silicone granulomas Fig. 2. MRI  showing silicone ﬁlled right axillary lymph node.
Formal histology of the specimen revealed a 6 mm grade 1, ER
positive, Her2 negative tubular carcinoma which was  completely
excised, the deep margin being nearest at 1 mm.  Five lymph nodes
were analysed from the sentinel lymph node biopsy all of which
were negative for metastatic disease. There was evidence of ﬂorid
granulomatous inﬂammation within all the nodes consistent with
silicone granulomas.
The patient declined postoperative radiotherapy but at her own
request underwent bilateral removal and exchange of implants
with capsulectomy by a plastic surgeon.
3. Discussion
SLNB for breast cancer was  rapidly incorporated into main-
stream practice after its introduction by Giuliano et al.8 SLNB is
now regarded as the surgical nodal staging technique of choice
for patients with clinically node negative disease. As experience
and comfort with the procedure has grown, studies have shown
that SLNB is both feasible and accurate in staging the axilla in
many clinical situations which may  have initially felt to represent
contraindications.9–12 The 2014 American Society Clinical Oncol-
ogy guidelines13 support the practice of SLNB in women with
previous non-oncological breast and axillary surgery.
Advances in implant technology have minimised the rate of sil-
icone lymphadenopathy by reducing release of gel from rupture
or bleeding of silicone. Zambacos et al.14 reported on silicone lym-
phadenopathy following implant augmentation before and after
the year 2000. Pre-2000, the mean age of implant at explantation
was 11.16 years compared to 4.06 years post-2000–the difference
accounted for by the vast number of PIP implants used post-2000.
Implant rupture and implications for subsequent SLNB is an
important topic. Authors of a recent case report have cautiouslying or ruptured silicone implants.7 There have been several other
studies describing the success of SLNB in augmented breasts but
none describe SLNB in patients in the presence of ruptured PIP
– 4×, 10× and 40× magniﬁcation (left to right).
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mplants.15,16 The use of non-medical grade silicone in PIP implants
dds another level of uncertainty. There is no evidence to suggest
hat despite the increase rate of rupture in such implants there is a
ink to cancer.
In the UK, it is estimated that over 40,000 women  had PIP
mplants for mainly cosmetic surgery (95%). Advice on removal of
hese devices has varied globally with certain countries (for exam-
le France) recommending the routine removal of these implants.
n expert advisory group in the UK convened by Professor Sir Bruce
eogh recommended that the routine removal of PIP implants in
he absence of symptoms was not necessary.17 In addition, the
HS would remove PIP implants but not replace them in circum-
tances where private clinics had failed to support this group of
omen. Much controversy still exists today and it is likely that
uture reviews will assess the regulation of cosmetic surgery prac-
ices.
Our case is the ﬁrst to our knowledge to describe SLNB in the
resence of a ruptured PIP implant and provides evidence that the
rocedure can be performed successfully. The sentinel lymph nodes
etrieved had evidence of blue dye and radioactivity conﬁrming
hat this is reliable even in the context of concurrent implant rup-
ure and the presence of silicone granulomas in axillary nodes.
These cases are complex and best managed in a multi-
isciplinary setting. Formal axillary dissection is likely to represent
ver-treatment in a subsequently node-negative axilla. In addition,
iscussions about adjuvant radiotherapy need to involve the radia-
ion oncologist and cosmetic surgeon as issues of post-radiotherapy
apsular contracture need to be considered and counselled appro-
riately.
In conclusion we suggest that SLNB is feasible in patients with
uptured PIP implants.
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